Literature DB >> 24903982

Stroke in patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study.

Anders M Greve1, Morten Dalsgaard2, Casper N Bang2, Kenneth Egstrup2, Simon Ray2, Kurt Boman2, Anne B Rossebø2, Christa Gohlke-Baerwolf2, Richard B Devereux2, Lars Køber2, Kristian Wachtell2.   

Abstract

BACKGROUND AND
PURPOSE: There are limited data on risk stratification of stroke in aortic stenosis. This study examined predictors of stroke in aortic stenosis, the prognostic implications of stroke, and how aortic valve replacement (AVR) with or without concomitant coronary artery bypass grafting influenced the predicted outcomes.
METHODS: Patients with mild-to-moderate aortic stenosis enrolled in the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. Diabetes mellitus, known atherosclerotic disease, and oral anticoagulation were exclusion criteria. Ischemic stroke was the primary end point, and poststroke survival a secondary outcome. Cox models treating AVR as a time-varying covariate were adjusted for atrial fibrillation and congestive heart failure, hypertension, age≥75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65-74 years and female sex (CHA2DS2-VASc) scores.
RESULTS: One thousand five hundred nine patients were followed for 4.3±0.8 years (6529 patient-years). Rates of stroke were 5.6 versus 21.8 per 1000 patient-years pre- and post-AVR; 429 (28%) underwent AVR and 139 (9%) died. Atrial fibrillation (hazard ratio [HR], 2.7; 95% confidence interval [CI], 1.1-6.6), CHA2DS2-VASc score (HR 1.4 per unit; 95% CI, 1.1-1.8), diastolic blood pressure (HR, 1.4 per 10 mm Hg; 95% CI, 1.1-1.8), and AVR with concomitant coronary artery bypass grafting (HR, 3.2; 95% CI, 1.4-7.2, all P≤0.026) were independently associated with stroke. Incident stroke predicted death (HR, 8.1; 95% CI, 4.7-14.0; P<0.001).
CONCLUSIONS: In patients with aortic stenosis not prescribed oral anticoagulation, atrial fibrillation, AVR with concomitant coronary artery bypass grafting, and CHA2DS2-VASc score were the major predictors of stroke. Incident stroke was strongly associated with mortality. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00092677.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  aortic valve stenosis; cardiac surgical procedures; risk factors; stroke

Mesh:

Substances:

Year:  2014        PMID: 24903982     DOI: 10.1161/STROKEAHA.114.005296

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  4 in total

1.  Association of Timing of Aortic Valve Replacement Surgery After Stroke With Risk of Recurrent Stroke and Mortality.

Authors:  Charlotte Andreasen; Mads Emil Jørgensen; Gunnar H Gislason; Andreas Martinsson; Robert D Sanders; Jawdat Abdulla; Per Føge Jensen; Christian Torp-Pedersen; Lars Køber; Charlotte Andersson
Journal:  JAMA Cardiol       Date:  2018-06-01       Impact factor: 14.676

2.  New-onset of postoperative atrial fibrillation is likely to recur in the absence of other triggers.

Authors:  Jesper Park-Hansen; Anders M Greve; Johan Clausen; Susanne J Holme; Christian L Carranza; Akhmadjon Irmukhamedov; Lubna Sabah; Qing Lin; Anne Sofie Madsen; Helena Domínguez
Journal:  Ther Clin Risk Manag       Date:  2018-09-07       Impact factor: 2.423

Review 3.  Arrhythmias in Patients With Valvular Heart Disease: Gaps in Knowledge and the Way Forward.

Authors:  Maciej Kubala; Christian de Chillou; Yohann Bohbot; Patrizio Lancellotti; Maurice Enriquez-Sarano; Christophe Tribouilloy
Journal:  Front Cardiovasc Med       Date:  2022-02-15

4.  Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban.

Authors:  Günter Breithardt; Helmut Baumgartner; Scott D Berkowitz; Anne S Hellkamp; Jonathan P Piccini; Yuliya Lokhnygina; Jonathan L Halperin; Daniel E Singer; Graeme J Hankey; Werner Hacke; Richard C Becker; Christopher C Nessel; Kenneth W Mahaffey; Robert M Califf; Keith A A Fox; Manesh R Patel
Journal:  Heart       Date:  2016-02-17       Impact factor: 5.994

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.